Results 21 to 30 of about 3,235 (226)

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR

Journal of Asthma and Allergy, 2023
Tanya M Laidlaw1,2 *, Andrew Menzies-Gow3 *, Scott Caveney,4 Joseph K Han,5 Nicole Martin,6,7 Elliot Israel,8 Jason K Lee,9,10 Jean-Pierre Llanos,11 Neil Martin,12,13 Ayman Megally,14 Bhavini Parikh,14 Sylvia Vong,15 Tobias Welte,16 Jonathan ...
Laidlaw TM, Menzies-Gow A, Caveney S, Han JK, Martin N, Israel E, Lee JK, Llanos JP, Martin N, Megally A, Parikh B, Vong S, Welte T, Corren J   +13 more
doaj   +1 more source

Biomarkers and clinical outcomes after tezepelumab cessation: extended follow-up from the 2-year DESTINATION study.

Annals of Allergy, Asthma & Immunology
BACKGROUND Long-term tezepelumab treatment in the DESTINATION study (NCT03706079) resulted in reduced asthma exacerbations, reduced biomarker levels and improved lung function and symptom control in patients with severe, uncontrolled asthma.
C. Brightling, M. Caminati, J. Llanos, S. Caveney, A. Kotalik, J. Griffiths, Anna Lundahl, E. Israel, Ian D. Pavord, M. Wechsler, C. Porsbjerg, J. Corren, M. Gołąbek, Neil Martin, S. Ponnarambil   +14 more
semanticscholar   +2 more sources

Real-life effectiveness of tezepelumab in severe asthma.

Allergologia et Immunopathologia
BACKGROUND Tezepelumab is a human monoclonal antibody which inhibits the cytokine thymic stromal lymphopoietin and is effective in different asthma endotypes.
J. C. Miralles-López, Francisco-José Bravo-Gutierrez, R. Andújar-Espinosa, M. Castilla-Martínez, C. Díaz-Chantar, M. Ramírez-Hernández, S. Cabrejos-Perotti, María Jesús Avilés-Inglés, I. Ibarra-Calabuig, Miguel Henrique Reyes-Cotes, M. J. Pajarón-Fernández, Roberto Bernabéu-Mora, Consuelo Alcalde-Rumayor, M. L. Alemany-Francés, J. Valverde-Molina, V. Pérez-Fernández, RE-ASGRAMUR GROUP   +16 more
semanticscholar   +3 more sources

Tezepelumab (Tezspire)

Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception ...
CDA-AMC
openaire   +2 more sources

Tezepelumab for severe asthma: elevating current practice to recognize epithelial driven profiles [PDF]

Respiratory Research
Background An increasing amount of evidence supports the relevance of epithelium across the wide spectrum of asthma pathobiology. On a clinical ground tezepelumab, selectively binding TSLP, a major epithelial cytokine, has demonstrated to be effective in
Marco Caminati, A. Vatrella, P. Rogliani, E. Carpagnano, A. Spanevello, G. Senna   +5 more
doaj   +2 more sources

Efficacy of tezepelumab in patients with severe asthma and persistent airflow obstruction

ERJ Open Research
Background Persistent airflow obstruction (PAO) in patients with asthma can be difficult to treat. Tezepelumab blocks thymic stromal lymphopoietin, an epithelial cytokine implicated in asthma pathogenesis.
Elliot Israel, Mario Castro, Christopher S. Ambrose, Jean-Pierre Llanos, Nestor A. Molfino, Nicole L. Martin, Sandhia S. Ponnarambil, Neil Martin   +7 more
doaj   +2 more sources

Dupilumab and tezepelumab in severe refractory asthma: new opportunities

Therapeutic Advances in Chronic Disease, 2022
Bronchial asthma is a chronic inflammatory condition with increasing prevalence worldwide that may present as heterogeneous phenotypes defined by the T2-mediated pattern of airway inflammation T2-high and T2-low asthma. Severe refractory asthma includes a subset of asthmatic patients who fail to control their disease despite maximal therapy and ...
Ragnoli, Beatrice, Morjaria, Jaymin, Pignatti, Patrizia, Montuschi, Paolo, Barbieri, Mariangela, Mondini, Lucrezia, Ruggero, Luca, Trotta, Liliana, Malerba, Mario   +8 more
openaire   +6 more sources

Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date

Drug Design, Development and Therapy, 2021
Zachariah L Dorey-Stein, Kartik V Shenoy Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USACorrespondence: Zachariah L Dorey-SteinDepartment of Thoracic Medicine and Surgery, Lewis Katz ...
Zachariah Dorey-Stein
exaly   +2 more sources

Three-dimensional bronchial tree visualization in exercise-induced severe asthma following tezepelumab treatment

Journal of Allergy and Clinical Immunology: Global
Airway hyperresponsiveness, a key feature of asthma, is associated with exercise-induced asthma. Tezepelumab was reported to reduce airway hyperresponsiveness.
Yoshiro Kai, MD, PhD, Yuichi Hishida, RT
doaj   +2 more sources

Tezepelumab for early-onset severe allergic asthma with persistent airflow limitation and small airway dysfunction: a treatable traits approach

Drugs in Context
We report the case of an 18-year-old woman with early-onset severe allergic asthma and no other type 2 biomarkers except the presence of IgE, complicated by persistent airflow limitation, air trapping and forced oscillation technique-defined small airway
Francesco Menzella, Claudio Sorino, Carlo Lombardi, Annamaria Bosi, Silvia Tonin, Lorenzo Corsi, Andrea Ballarin, Marcello Cottini   +7 more
doaj   +2 more sources